Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Yumi Nishio"'
Autor:
Eiichi Nakayama, Mikio Oka, Akiko Uenaka, Minoru Fukuda, Midori Isobe, Yumi Nishio, Hirofumi Matsumoto, Yu Mizote, Koji Kurose, Yoshihiro Ohue
Representative results of analyses of CD4 (A) and CD8 (B) T cells expressing T cell activation and inhibitory molecules in PBMCs from an XAGE1 (GAGED2a) antibody-positive patient, KLU456 by FACS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e8cdbbdde61d4e88e9d4d3322391793
https://doi.org/10.1158/1078-0432.22460087
https://doi.org/10.1158/1078-0432.22460087
Autor:
Eiichi Nakayama, Mikio Oka, Akiko Uenaka, Minoru Fukuda, Midori Isobe, Yumi Nishio, Hirofumi Matsumoto, Yu Mizote, Koji Kurose, Yoshihiro Ohue
OS of the advanced adenocarcinoma patients with EGFRwt or EGFRmt tumors (A), and with XAGE1 (GAGED2a) antigen-positive EGFRwt or EGFRmt tumors and antibody, and XAGE1 (GAGED2a) antigen-negative EGFRmt tumors (B).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96dd30d9b654dc811d3a56eb6ea748b9
https://doi.org/10.1158/1078-0432.22460081
https://doi.org/10.1158/1078-0432.22460081
Autor:
Eiichi Nakayama, Mikio Oka, Akiko Uenaka, Minoru Fukuda, Midori Isobe, Yumi Nishio, Hirofumi Matsumoto, Yu Mizote, Koji Kurose, Yoshihiro Ohue
Supplementary Table 1A. Patient characteristics (n=145). Supplementary Table 1B. EGFR mutation types (n=44). Supplementary Table 2A. Univariate Cox regression analysis. Supplementary Table 2B. Multivariate Cox regression analysis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64ef367b06b84e8f374798314cfc035a
https://doi.org/10.1158/1078-0432.22460069.v1
https://doi.org/10.1158/1078-0432.22460069.v1
Autor:
Eiichi Nakayama, Mikio Oka, Akiko Uenaka, Minoru Fukuda, Midori Isobe, Yumi Nishio, Hirofumi Matsumoto, Yu Mizote, Koji Kurose, Yoshihiro Ohue
Purpose: The cancer/testis antigen XAGE1 (GAGED2a) is expressed in approximately 40% of advanced lung adenocarcinomas. We investigated the clinical relevance of the XAGE1 (GAGED2a) immune responses in patients with advanced lung adenocarcinoma.Experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8945b37789aadb151a4fda5a5405ae04
https://doi.org/10.1158/1078-0432.c.6524396
https://doi.org/10.1158/1078-0432.c.6524396
Autor:
Eiichi Nakayama, Mikio Oka, Akiko Uenaka, Minoru Fukuda, Midori Isobe, Yumi Nishio, Hirofumi Matsumoto, Yu Mizote, Koji Kurose, Yoshihiro Ohue
OS of the advanced lung adenocarcinoma patients with different EGFR mutation types.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b2caacc516b9b36862c535b3903722c
https://doi.org/10.1158/1078-0432.22460078
https://doi.org/10.1158/1078-0432.22460078
Autor:
Eiichi Nakayama, Mikio Oka, Akiko Uenaka, Minoru Fukuda, Midori Isobe, Yumi Nishio, Hirofumi Matsumoto, Yu Mizote, Koji Kurose, Yoshihiro Ohue
ICS of CD4 and CD8 T cells reactive against XAGE1 (GAGED2a).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61a4975b91eb4e4eaf21f1d6b2f4eb62
https://doi.org/10.1158/1078-0432.22460093.v1
https://doi.org/10.1158/1078-0432.22460093.v1
Autor:
Eiichi Nakayama, Mikio Oka, Akiko Uenaka, Minoru Fukuda, Midori Isobe, Yumi Nishio, Hirofumi Matsumoto, Yu Mizote, Koji Kurose, Yoshihiro Ohue
Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1208395a31716ada9f574001c2bbe111
https://doi.org/10.1158/1078-0432.22460075.v1
https://doi.org/10.1158/1078-0432.22460075.v1
Autor:
Eiichi Nakayama, Mikio Oka, Akiko Uenaka, Minoru Fukuda, Midori Isobe, Yumi Nishio, Hirofumi Matsumoto, Yu Mizote, Koji Kurose, Yoshihiro Ohue
Correlation of OS with XAGE1 (GAGED2a) antibody titer in patients with XAGE1 (GAGED2a) antigen-positive tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::640284306a831dc571724bbf0cc927c7
https://doi.org/10.1158/1078-0432.22460084.v1
https://doi.org/10.1158/1078-0432.22460084.v1
Autor:
Kouji Takimoto, Yumi Nishio, Masato Kawasaki, Ryousuke Katsura, Masato Kurokawa, Junko Kusaka
Publikováno v:
Skin Cancer. 29:48-52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6c13eda054bd6013a0a1b4cfae39ced
https://doi.org/10.5227/skincancer.29.48
https://doi.org/10.5227/skincancer.29.48
Publikováno v:
Cancer Research. 77:2932-2932
Introduction and Purpose: Recently, immune checkpoint therapy has been incorporated into treatment of solid cancers including lung cancer, resulted in prolonged survival benefit. Checkpoint inhibitors target on PD-1/PD-L1 or CTLA-4 immuno-inhibitory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23c70eabec450174a837a5f3f9f9bed6
https://doi.org/10.1158/1538-7445.am2017-2932
https://doi.org/10.1158/1538-7445.am2017-2932